BD attending Finland’s HealthBio 2014 Annual Seminar - Global healthcare companies continue to be interested in Finnish Life Science expertise
The annual meeting highlighting Finnish Biotech expertise, the HealthBIO Seminar, will attract 200 industry representatives to Turku on Wednesday, August 27th. This year, BD (Becton, Dickinson and Company), a global medical technology company, will also participate in the event organized by BioTurku®.
BD develops, manufactures and sells medical devices, instrument systems and reagents globally. BD maintains a regional office in Finland, but this is the first time the company will send representatives from its U.S. headquarters to participate in the HealthBIO event.
”As part of our efforts to seek ‘the best science and technology outside our walls’, we are looking forward to the conference and subsequent discussions with representatives of Finnish Life Science companies and research institutions. The Finnish biotechnology community has an outstanding global reputation for high quality technology, and products and we hope these initial meetings will lead to several productive collaborations,” says Ellen Strahlman, Senior Vice President, Research & Development at BD.
”The fact that a company that operates in more than 50 countries, generates more than 8 billion dollars in annual revenue, and employs nearly 30,000 people is interested in life science expertise in Finland indicates a very positive outlook for Finnish companies in this line of business. It’s also an important signal that the investments made in research and development in life sciences over the years bear fruit,” says Reijo Salonen, Senior Vice President, Research and Development of Orion Corporation.
BioTurku® has already been organizing HealthBIO seminars for a total of ten years.
”Attending healthcare companies find this event to be their most important annual meeting, where they can discuss industry trends and cooperation opportunities”, says Tero Piispanen, Program Director of Turku Science Park Ltd, the company coordinating BioTurku®.
The annual HealthBIO Seminar will be held in Turku at Conference Centre Mauno (BioCity, Tykistökatu 6) on Wednesday, August 27th. Representatives of the media are welcome to the seminar. Ellen Strahlman, BD’s Senior Vice President and Chief Medical Officer, will address attendees in the afternoon.
Program available at www.turkusciencepark.com/tapahtumat
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
About Turku Science Park Ltd
Turku Science Park Ltd is an accelerator of innovative growth. It promotes the utilisation of university-based expertise and competitiveness of enterprises as well as generating new business especially in the fields of biotechnology (BioTurku® - Life Science and materials technology) and information and communication technology (ICT Turku). The principal owner of Turku Science Park Ltd is the City of Turku. www.turkusciencepark.com.
BioTurku®, coordinated by Turku Science Park Ltd, focuses on the expertise in human health within the Life Science field. Pharmaceutical industry and diagnostics are traditionally strong areas. Turku region enterprises generate nearly half of the turnover of Finnish pharmaceutical industry. Special areas of application include hormonal diseases and cancer, inflammatory and infectious diseases, as well as central nervous system diseases. These established Life Science strengths are complemented by materials and nanotechnology. www.turkusciencepark.com/bioturku.